BioPharm Business News

Thursday, January 08, 2009
BioMarin Bets $289 Million That Riquent Works in Lupus Nephritis
BioMarin has bet $289 million that the third time is the charm for La Jolla Pharmaceutical's experimental lupus drug Riquent^® (abetimus sodium), which failed to reach primary endpoints in 2 previous clinical trials...

Thursday, December 11, 2008
One-Shot Synvisc Gets FDA Panel OK
An FDA advisory panel has unanimously recommended approval of Genzyme's Synvisc-One™ single-dose hyalin for knee OA pain...

Thursday, December 04, 2008
FDA Panel Okays Febuxostat for Gout
A US FDA panel voted 12-0 this week to recommend approval of Takeda Pharmaceutical's febuxostat (Uloric^®), the first new gout drug in 40 years...

Friday, November 21, 2008
EntreMed Reports Antiangiogenic Role of 2ME2 Demonstrated in RA Models
Preclinical results for 2ME2 (Panzem^® or 2-methoxyestradiol) in rheumatoid arthritis demonstrated that 2ME2 involutes rat collagen-induced arthritis and suppresses synovial VEGF and bFGF gene expression...

Thursday, November 20, 2008
BioLineRx, Yissum Sign a Licensing Agreement for the Development of an Anti-Leptin Compound for the Treatment of IBD
BioLineRx signed an exclusive license agreement with Yissum Ltd to develop and commercialize BL-5040, an antagonist of leptin with anti-inflammatory properties for the treatment of inflammatory bowel disease (IBD)...

Tuesday, November 18, 2008
Phosphagenics’ Transdermal Diclofenac Enters Phase I Clinical Trial
The trial will compare the bioavailability and penetration of the topically applied Voltaren^® gel (1% diclofenac sodium topical gel, Novartis), and Phosphagenics’ TPM/diclofenac (at 1% and 2% diclofenac concentrations) for the targeted delivery of the NSAID diclofenac...